Appendix 4E and 2022 Annual Report
Filed with ASX · · 82 pages · English
There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $6,780,363 (30 June 2021: $4,062,920). During the period, the Group had total income of $3,333,576 (2021: $1,338,377), consisting of the R&D tax incentive of $3,297,980 (2021: $1,188,581), licencing revenue of $27,500 (2021: $27,500)
In the deck
Story so far
Earlier from Patrys
- PAT-DX1 From Engineering Run Meets all Specification Tests
- New Research Grant For Deoxymabs in Metastatic Breast Cancer
- PAT-DX1/Radiation Combination Improves Brain Cancer Survival
- Appendix 4C - Quarterly - 30 June 2022
- PAT-DX1 Engineering Run Successfully Completed
Later from Patrys
- PAT DX3 Crosses Blood Brain Barrier in Healthy Animals
- Appendix 4C - Quarterly - 30 September 2022
- Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
- Response to ASX Price Query
- Appendix 4C - Quarterly - 31 December 2022
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys